A Comparison of 2-Phenyl-2-(1-piperidinyl)propane (PPP), 1,1′,1″-Phosphinothioylidynetrisaziridine (ThioTEPA), Clopidogrel, and Ticlopidine as Selective Inactivators of Human Cytochrome P450 2B6

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Drug Metabolism And Disposition

• Publication date

  2007-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.107.015883PMID 17682072
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions

  2007cited by this paper
• Antiplatelet Agents Aspirin and Clopidogrel Are Hydrolyzed by Distinct Carboxylesterases, and Clopidogrel Is Transesterificated in the Presence of Ethyl Alcohol

  2006cited by this paper
• Effect of Clopidogrel and Ticlopidine on Cytochrome P450 2B6 Activity as Measured by Bupropion Hydroxylation

  2005cited by this paper
• Inhibition of human CYP2B6 by N,N',N''-triethylenethiophosphoramide is irreversible and mechanism-based.

  2005influential reference
• SELECTIVE INHIBITION OF HUMAN CYTOCHROME P4502C8 BY MONTELUKAST

  2005influential reference
• SERTRALINE IS METABOLIZED BY MULTIPLE CYTOCHROME P450 ENZYMES, MONOAMINE OXIDASES, AND GLUCURONYL TRANSFERASES IN HUMAN: AN IN VITRO STUDY

  2005cited by this paper
• Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine

  2004influential reference
• Metabolism of N,N′,N″-Triethylenethiophosphoramide by CYP2B1 and CYP2B6 Results in the Inactivation of Both Isoforms by Two Distinct Mechanisms

  2004cited by this paper
• Validated assays for human cytochrome P450 activities.

  2004influential reference
• Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro.

  2004cited by this paper
• The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity

  2003cited by this paper
• The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

  2003influential reference
• Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions.

  2003influential reference
• Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism.

  2002cited by this paper
• In vitro approaches for studying the inhibition of drug metabolism enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs

  2002cited by this paper
• Drug-Drug Interactions

  2001cited by this paper
• Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide.

  2000cited by this paper
• Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.

  2000cited by this paper
• CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.

  2000cited by this paper
• Mechanism-based inactivation of cytochromes P450 2B1 and P450 2B6 by 2-phenyl-2-(1-piperidinyl)propane.

  2000cited by this paper
• Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles.

  1999cited by this paper
• Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes.

  1999cited by this paper
• Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro.

  1999cited by this paper
• Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes.

  1997cited by this paper
• Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes.

  1993cited by this paper
• Pharmacological significance of the species differences in bupropion metabolism.

  1987cited by this paper

• Cytochrome P450 in GtoPdb v.2025.3

  2025cites this paper
• Probing into the plasma stability and microsomal stability of thiol-based prodrug derivatives: Using IYS-15, an HDAC inhibitor as the model thiol.

  2025cites this paper
• A Review of CYP-Mediated Drug Interactions: Mechanisms and In Vitro Drug-Drug Interaction Assessment

  2024cites this paper
• Ionic Liquid 1-Octyl-3-Methylimidazolium (M8OI) Is Mono-Oxygenated by CYP3A4 and CYP3A5 in Adult Human Liver

  2024cites this paper
• Decreased plasma exposure of clopidogrel active metabolite in rats after long‐term treatment with clopidogrel

  2023influential citation
• Metabolism of Speciociliatine, an Overlooked Kratom Alkaloid for its Potential Pharmacological Effects

  2022influential citation
• Hepatic CYP2B10 is highly induced by binge ethanol and contributes to acute-on-chronic alcohol-induced liver injury.

  2022cites this paper
• Characteristics of cytochrome P450-dependent metabolism against acetamiprid in the musk shrew (Suncus murinus).

  2022cites this paper
• Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug–Drug–Gene Interaction Predictions

  2022cites this paper
• Prospective Prediction of Dapaconazole Clinical Drug–Drug Interactions Using an In Vitro to In Vivo Extrapolation Equation and PBPK Modeling

  2022cites this paper
• The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans

  2022cites this paper
• Defining the Selectivity of Chemical Inhibitors Used for Cytochrome P450 Reaction Phenotyping: Overcoming Selectivity Limitations with a Six-Parameter Inhibition Curve-Fitting Approach

  2022cites this paper
• Cytochrome P450 in GtoPdb v.2021.2

  2021cites this paper
• Drug‐Metabolizing Enzymes and Drug Toxicity

  2021cites this paper
• Human Family 1–4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update

  2021cites this paper
• Investigation of CYP2B6, 3A4 and β-esterase interactions of Withania somnifera (L.) Dunal in human liver microsomes and HepG2 cells.

  2021cites this paper
• Impact of cytochrome P450 variation on meperidine N-demethylation to the neurotoxic metabolite normeperidine

  2020cites this paper
• Highly productive and scalable approach to synthesize ticlopidine: A potent thienopyridine anti-platelet aggregation drug

  2020cites this paper
• Risk assessment of the chiral pesticide fenamiphos in a human model: Cytochrome P450 phenotyping and inhibition studies.

  2020cites this paper
• Inhibition and induction of CYP enzymes in humans: an update

  2020cites this paper
• Screening of ten cytochrome P450 enzyme activities with 12 probe substrates in human liver microsomes using cocktail incubation and liquid chromatography–tandem mass spectrometry

  2019cites this paper
• Evaluation of the enantioselective in vitro metabolism of the chiral pesticide fipronil employing a human model: Risk assessment through in vitro-in vivo correlation and prediction of toxicokinetic parameters.

  2019cites this paper
• In vitro enantioselective study of the toxicokinetic effects of chiral fungicide tebuconazole in human liver microsomes.

  2019cites this paper
• Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of Mitragyna speciosa (kratom)

  2019cites this paper
• Quantitative in vitro phenotyping and prediction of drug interaction potential of CYP2B6 substrates as victims

  2018cites this paper
• Site-specific oxidation of flavanone and flavone by cytochrome P450 2A6 in human liver microsomes

  2018cites this paper
• Which cytochrome P450 metabolizes phenazepam? Step by step in silico, in vitro, and in vivo studies

  2018cites this paper
• Anti-HIV Drug Human Biotransformation and Structure-Activity Relationship of Pregnane X Receptor Activation

  2016influential citation
• Development of a Specific Substrate—Inhibitor Panel (Liver-on-a-Chip) for Evaluation of Cytochrome P450 Activity

  2016cites this paper
• Chemical inhibitors of CYP450 enzymes in liver microsomes: combining selectivity and unbound fractions to guide selection of appropriate concentration in phenotyping assays

  2015cites this paper
• Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction.

  2015cites this paper
• Identification of human cytochrome P450 isozymes involved in the metabolism of naftopidil enantiomers in vitro

  2014cites this paper
• High-throughput fluorescence assay for cytochrome P450 mechanism-based inactivators.

  2013cites this paper
• Human Biotransformation of the Nonnucleoside Reverse Transcriptase Inhibitor Rilpivirine and a Cross-Species Metabolism Comparison

  2013cites this paper
• Challenges in exploring the cytochrome P450 system as a source of variation in canine drug pharmacokinetics

  2013cites this paper
• Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance

  2013cites this paper
• Comparison of p450 enzymes between cynomolgus monkeys and humans: p450 identities, protein contents, kinetic parameters, and potential for inhibitory profiles.

  2013cites this paper
• Mechanisms and quantitative prediction of Efavirenz metabolism, pharmacogenetics and drug interactions

  2013influential citation
• Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.

  2013cites this paper
• Cytochrome P450 2B6: function, genetics, and clinical relevance

  2012cites this paper
• Biotransformation of the Antiretroviral Drug Etravirine: Metabolite Identification, Reaction Phenotyping, and Characterization of Autoinduction of Cytochrome P450-Dependent Metabolism

  2012cites this paper
• Effects of sertraline on the pharmacokinetics of bupropion and its major metabolite, hydroxybupropion, in mice

  2012influential citation
• Characterization of intestinal and hepatic P450 enzymes in cynomolgus monkeys with typical substrates and inhibitors for human P450 enzymes

  2012cites this paper
• Risk Assessment of Mechanism-Based Inactivation in Drug-Drug Interactions

  2012cites this paper
• Liver-based in vitro technologies for drug biotransformation studies - a review.

  2012cites this paper
• Drug interaction study between bupropion and ticlopidine in male CF-1 mice.

  2011cites this paper
• Metabolism of dl-praeruptorin a in rat liver microsomes using HPLC-electrospray ionization tandem mass spectrometry

  2011cites this paper
• Potential of hydroxyebastine and terfenadine alcohol to inhibit the human cytochrome P450 2J2 isoform

  2011cites this paper
• Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation.

  2011cites this paper
• Alternative Androgen Metabolism in Resistance to Aromatase Inhibitors.

  2011cites this paper
• Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity

  2011cites this paper
• Mechanism-Based Inactivation of Human Cytochrome P450 2B6 by Clopidogrel: Involvement of Both Covalent Modification of Cysteinyl Residue 475 and Loss of Heme

  2011cites this paper
• The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.

  2010cites this paper
• Inactivation of Human Cytochrome P450 Enzymes and Drug–Drug Interactions

  2010cites this paper
• The role of metabolites in predicting drug-drug interactions: Focus on irreversible P450 inhibition

  2010cites this paper
• Efavirenz Primary and Secondary Metabolism In Vitro and In Vivo: Identification of Novel Metabolic Pathways and Cytochrome P450 2A6 as the Principal Catalyst of Efavirenz 7-Hydroxylation

  2010cites this paper
• Measurement of In Vitro Cytochrome P450 2B6 Activity

  2009cites this paper
• A Predominate Role of CYP1A2 for the Metabolism of Nabumetone to the Active Metabolite, 6-Methoxy-2-naphthylacetic Acid, in Human Liver Microsomes

  2009cites this paper
• Mechanism-Based Inhibition of Human Cytochrome P450 2B6 by Ticlopidine, Clopidogrel, and the Thiolactone Metabolite of Prasugrel

  2009cites this paper
• Decreased Susceptibility of the Cytochrome P450 2B6 Variant K262R to Inhibition by Several Clinically Important Drugs

  2009cites this paper
• New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I.

  2009cites this paper
• A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA), in human liver microsomes

  2009cites this paper
• Cytochrome P450 2B6 Catalyzes the Formation of Pharmacologically Active Sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) Metabolites in Human Liver Microsomes

  2008cites this paper
• Decreased Susceptibility of the Cytochrome P450 2B6 Variant K262R to Inhibition by Several Clinically Important Drugs

  2008cites this paper
• CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.

  2008cites this paper
• Cytochrome P 450 2 B 6 Catalyzes the Formation of Pharmacologically Active Sibutramine ( N-{ 1-[ 1-( 4-chlorophenyl ) cyclobutyl ]-3-methylbutyl }-N , N-dimethylamine ) Metabolites in Human Liver Microsomes

  year unknowncites this paper